Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma
Authors not listed
Jonsson Comprehensive Cancer Center · 2010
Abstract
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as temozolomide, also work in different ways to kill tumor cells or stop them from growing. Giving bevacizumab together with temozolomide may be a better way to block tumor growth.
PURPOSE: This phase II trial is studying how well giving bevacizumab and temozolomide together works in treating older patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2010). Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma. <em>Jonsson Comprehensive Cancer Center</em>. https://clinicaltrials.gov/study/NCT01149850
Vancouver
Anonymous. Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma. Jonsson Comprehensive Cancer Center. 2010.
BibTeX
@misc{anon2010PhaseI,
title = {Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma},
author = {Anonymous},
journal = {Jonsson Comprehensive Cancer Center},
year = {2010},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Barbara Ann Karmanos Cancer Institute 2008
Open access · US-GOV
Evaluation of Bevacizumab and Weekly Docetaxel in Elderly (≥ 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Alliance for Clinical Trials in Oncology 2008
Open access · US-GOV
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2)
Centre Antoine Lacassagne 2007
Open access · US-GOV
International Phase II Study Evaluating the Association of CHOP-rituximab With Consolidation by Early Ibritumomab Tiuxetan-Y90 in Patients Aged 65 to 80 Years With CD20+ Large Cell Malignant Lymphoma and no Prior Therapy
Canadian Cancer Trials Group 2007
Open access · US-GOV
A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
German High-Grade Non-Hodgkin's Lymphoma Study Group 2004
Open access · US-GOV
2-Weekly CHOP Chemotherapy With Dose-Dense Rituximab for the Treatment of Patients Aged 61 to 80 Years With Aggressive CD-20 Positive B-Cell Lymphomas: A Phase-II/Pharmacokinetic Study (CHOP-R-ESC)
German High-Grade Non-Hodgkin's Lymphoma Study Group 2005
Open access · US-GOV